About: A Porcine Adenovirus with Low Human Seroprevalence Is a Promising Alternative Vaccine Vector to Human Adenovirus 5 in an H5N1 Virus Disease Model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Porcine Adenovirus with Low Human Seroprevalence Is a Promising Alternative Vaccine Vector to Human Adenovirus 5 in an H5N1 Virus Disease Model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Porcine Adenovirus with Low Human Seroprevalence Is a Promising Alternative Vaccine Vector to Human Adenovirus 5 in an H5N1 Virus Disease Model
Creator	Patel, A Kobinger, G Tikoo, S
Source	PMC
abstract	Human adenovirus 5 (AdHu5) vectors are robust vaccine platforms however the presence of naturally-acquired neutralizing antibodies may reduce vector efficacy and potential for re-administration. This study evaluates immune responses and protection following vaccination with a replication-incompetent porcine adenovirus 3 (PAV3) vector as an alternative vaccine to AdHu5 using an avian influenza H5N1 disease model. Vaccine efficacy was evaluated in BALB/c mice following vaccination with different doses of the PAV3 vector expressing an optimized A/Hanoi/30408/2005 H5N1 hemagglutinin antigen (PAV3-HA) and compared with an AdHu5-HA control. PAV3-HA rapidly generated antibody responses, with significant neutralizing antibody titers on day 21, and stronger cellular immune responses detected on day 8, compared to AdHu5-HA. The PAV3-HA vaccine, administered 8 days before challenge, demonstrated improved survival and lower virus load. Evaluation of long-term vaccine efficacy at 12 months post-vaccination showed better protection with the PAV3-HA than with the AdHu5-HA vaccine. Importantly, as opposed to AdHu5, PAV3 vector was not significantly neutralized by human antibodies pooled from over 10,000 individuals. Overall, PAV3-based vector is capable of mediating swift, strong immune responses and offer a promising alternative to AdHu5.
has issue date	2010-12-16(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0015301
bibo:pmid	21179494
has license	cc-by
sha1sum (hex)	f46d2803581226a9a94026693e95db88e7c70641
schema:url	https://doi.org/10.1371/journal.pone.0015301
resource representing a document's title	A Porcine Adenovirus with Low Human Seroprevalence Is a Promising Alternative Vaccine Vector to Human Adenovirus 5 in an H5N1 Virus Disease Model
has PubMed Central identifier	PMC3002947
has PubMed identifier	21179494
schema:publication	PLoS One
resource representing a document's body	covid:f46d2803581226a9a94026693e95db88e7c70641#body_text
is schema:about of	named entity 'VIRUS DISEASE' named entity 'PORCINE ADENOVIRUS' named entity 'Overall' named entity 'alternative' named entity 'platforms' named entity 'neutralizing antibodies' named entity 'rapidly' named entity 'avian influenza' named entity 'Virus' named entity 'Adenovirus' named entity 'ALTERNATIVE' named entity 'LOW' named entity 'HUMAN' named entity 'BETTER' named entity 'HUMAN' named entity 'PRESENCE OF' named entity 'INDIVIDUALS' named entity 'VACCINE EFFICACY' named entity 'IMMUNE RESPONSES' named entity 'POST' named entity 'ANTIGEN' named entity 'ALTERNATIVE' named entity 'USING' named entity 'SIGNIFICANT' named entity 'HUMAN ADENOVIRUS 5' named entity 'VACCINATION' named entity 'PROTECTION' named entity 'INCOMPETENT' named entity 'POOLED' named entity 'NEUTRALIZING ANTIBODY' named entity 'VECTOR' named entity 'OFFER' named entity 'OVERALL' named entity 'DEMONSTRATED' named entity 'POTENTIAL' named entity 'DETECTED' named entity 'MICE' named entity 'DIFFERENT' named entity 'BASED' named entity 'NEUTRALIZING ANTIBODIES' named entity 'AVIAN INFLUENZA' named entity 'CELLULAR' named entity 'FOLLOWING' named entity 'COMPARED' named entity 'DAY' named entity 'STUDY' named entity 'HUMAN ADENOVIRUS 5' named entity 'EVALUATION' named entity 'SWIFT' named entity 'H5N1' named entity 'HEMAGGLUTININ' named entity 'LONG-TERM' named entity '10%' named entity 'BALB' named entity 'VECTORS' named entity 'ROBUST' named entity 'SEROPREVALENCE' named entity 'RESPONSES' named entity 'H5N1 VIRUS' named entity 'IS A' named entity 'DISEASE MODEL' named entity 'ADMINISTERED' named entity 'IMPROVED' named entity 'CAPABLE' named entity 'VIRUS LOAD' named entity '12 MONTHS' named entity 'ANTIBODY TITERS' named entity 'SURVIVAL' named entity 'REDUCE' named entity 'RE-ADMINISTRATION' named entity 'STRONG' named entity 'CHALLENGE' named entity 'ACQUIRED' named entity 'GENERATED' named entity 'DAYS' named entity 'VECTOR' named entity 'PORCINE ADENOVIRUS 3' named entity 'EFFICACY' named entity 'EVALUATED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software